<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>Test_Domande</title><meta name="author" content="federico liparulo"/><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 p { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12pt; margin:0pt; }
 h1 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 12pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 1; }
 #l1> li:before {counter-increment: c1; content: counter(c1, decimal)". "; color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12pt; }
 #l1> li:first-child:before {counter-increment: c1 0;  }
 #l2 {padding-left: 0pt;counter-reset: c2 1; }
 #l2> li:before {counter-increment: c2; content: counter(c2, lower-latin)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l2> li:first-child:before {counter-increment: c2 0;  }
 #l3 {padding-left: 0pt;counter-reset: c2 1; }
 #l3> li:before {counter-increment: c2; content: counter(c2, lower-latin)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l3> li:first-child:before {counter-increment: c2 0;  }
 #l4 {padding-left: 0pt;counter-reset: c2 1; }
 #l4> li:before {counter-increment: c2; content: counter(c2, lower-latin)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l4> li:first-child:before {counter-increment: c2 0;  }
 #l5 {padding-left: 0pt;counter-reset: c2 1; }
 #l5> li:before {counter-increment: c2; content: counter(c2, lower-latin)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l5> li:first-child:before {counter-increment: c2 0;  }
 #l6 {padding-left: 0pt;counter-reset: c2 1; }
 #l6> li:before {counter-increment: c2; content: counter(c2, lower-latin)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l6> li:first-child:before {counter-increment: c2 0;  }
 #l7 {padding-left: 0pt;counter-reset: c2 1; }
 #l7> li:before {counter-increment: c2; content: counter(c2, lower-latin)". "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l7> li:first-child:before {counter-increment: c2 0;  }
</style></head><body><p style="padding-top: 1pt;padding-left: 308pt;text-indent: 0pt;text-align: left;">Federico Liparulo - Raffaele Mazzella</p><p style="text-indent: 0pt;text-align: left;"><br/></p><h1 style="padding-top: 2pt;padding-left: 4pt;text-indent: 0pt;text-align: center;">Domande CORE primo appello Gennaio 2021</h1><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l1"><li style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Radioterapia 1: Quale è l&#39;opzione terapeutica di scelta in pazienti affetti da NSCLC stadio I</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 15pt;text-align: left;">con multiple comorbidità:</p><ol id="l2"><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><h1 style="display: inline;">Radioterapia stereotassica</h1></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Pneumectomia + Linfadenectomia mediastinica</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Lobectomia senza linfadenectomia mediastinica</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Chemioterapia</p></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Tutte le precedenti</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ol></li><li style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Radioterapia 2: Come si definisce un paziente affetto da NSCLC IV stadio con 4 lesioni secondarie metastatiche:</p><ol id="l3"><li style="padding-left: 77pt;text-indent: -18pt;line-height: 14pt;text-align: left;"><p style="display: inline;">Oligoprogressivo</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Plurimetastatico</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Pluricorrente</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><h1 style="display: inline;">Oligometastatico</h1></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Oligoricorrente</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ol></li><li style="padding-left: 41pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Radioterapia 3: I sarcomi si localizzano più frequentemente:</p><ol id="l4"><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">In sede cervico-facciale</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Al retroperitoneo</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><h1 style="display: inline;">Agli arti</h1></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Al tronco</p></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">A livello dei tegumenti</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ol></li><li style="padding-left: 41pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Radioterapia 4: Quali delle seguenti affermazioni è vera:</p><ol id="l5"><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><h1 style="display: inline;">Il trattamento del sarcoma retroperitoneale dipende dalla istologia</h1></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">L&#39;ipertermia è sempre indicata nel trattamento dei sarcomi retroperitoneali</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">La radioterapia non è indicata nel trattamento del sarcoma retroperitoneale</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Il sarcoma retroperitoneale va trattato sempre con la sola chirurgia</p></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Il sarcoma retroperitoneale si tratta esclusivamente con la chemioterapia e la radioterapia</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ol></li><li style="padding-left: 41pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Radioterapia 5: Quale di queste affermazioni relative al trattamento del linfoma testicolare</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 15pt;text-align: left;">è falsa:</p><ol id="l6"><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Nei pazienti con coinvolgimento linfonodale le stazioni linfonodali positive all&#39;esordio</p><p style="padding-left: 77pt;text-indent: 0pt;line-height: 15pt;text-align: left;">sono incluse nei volumi di trattamento</p></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><h1 style="display: inline;">Le dosi di radioterapia devono essere molto elevate in quanto è un linfoma radioresistente</h1></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 14pt;text-align: left;"><p style="display: inline;">La radioterapia nel linfoma testicolare prevede l&#39;irradiazione del testicolo</p><p style="padding-left: 77pt;text-indent: 0pt;line-height: 15pt;text-align: left;">controlaterale</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">La terapia è multimodale</p></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">La radioterapia prevede dosi totali di 25-30 Gy</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li></ol></li><li style="padding-left: 41pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Radioterapia 6: Dove origina più frequentemente il tumore del rinofaringe:</p><ol id="l7"><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Parete superiore del rinofaringe</p></li><li style="padding-left: 77pt;text-indent: -18pt;line-height: 15pt;text-align: left;"><p style="display: inline;">Parete anteriore del rinofaringe</p></li><li style="padding-left: 77pt;text-indent: -18pt;text-align: left;"><p style="display: inline;">Parete inferiore del rinofaringe</p></li></ol></li></ol></body></html>
